FDA: What It Is and Why It Matters

The U.S. Food and Drug Administration is one of the oldest and most consequential federal regulatory agencies in the United States, responsible for overseeing products that collectively account for roughly 20 cents of every consumer dollar spent in the American economy (FDA, "What We Do"). This page covers the agency's scope, legal authority, internal architecture, and the mechanisms through which it exercises regulatory power. It draws on a library of more than 48 detailed reference pages on this site — spanning drug approval pathways, device classification, food safety law, enforcement actions, and public health emergency response — to give readers a structured entry point into the full breadth of FDA's operational domain.

Scope and Definition

The FDA operates under the Federal Food, Drug, and Cosmetic Act (FD&C Act), first enacted in 1938, as well as the Public Health Service Act and more than 200 additional statutory authorities (FDA, Legal Authority). Its jurisdiction extends to human and animal drugs, biological products, medical devices, food and dietary supplements, cosmetics, tobacco products, and radiation-emitting electronic products. The agency does not regulate all consumable products — the U.S. Department of Agriculture holds primary jurisdiction over meat, poultry, and processed egg products — but the boundary of FDA authority still touches an estimated $2.8 trillion worth of products sold annually in the United States (FDA, "What We Do").

Understanding the precise edges of FDA jurisdiction is not an academic exercise. A company that misclassifies a product — treating a drug-device combination as a standalone device, for example — may undergo the wrong premarket review pathway, triggering enforcement consequences including import detention, injunctions, or consent decrees. The FDA mission and authority page details the statutory foundations and jurisdictional limits that define these boundaries.

For a deeper look at how the agency reached its present form, the FDA history and milestones page traces key legislative and enforcement turning points, from the sulfanilamide disaster of 1937 through the Food Safety Modernization Act of 2011.

Why This Matters Operationally

Regulatory failures under FDA oversight carry measurable consequences. A single Class I recall — the category FDA reserves for products with reasonable probability of causing serious adverse health consequences or death — can expose a manufacturer to costs running into the tens of millions of dollars before litigation is factored in. The agency issued 47 Class I drug recalls in fiscal year 2022 alone (FDA, Recalls Database).

Beyond recall liability, the FDA's authority to issue warning letters, seize products, pursue injunctions, and refer criminal matters to the Department of Justice creates a layered enforcement environment. Companies operating in regulated product categories cannot treat FDA compliance as a back-office function. The FDA enforcement actions and recalls section covers these mechanisms in detail.

The agency also controls market access. No new prescription drug reaches U.S. patients without FDA approval. No high-risk medical device reaches the market without premarket approval (PMA) or an equivalent authorization. This gatekeeping function means FDA decisions directly shape competitive dynamics across pharmaceutical, biotechnology, and medical device sectors. Questions about how that system works in practice — from initial application through post-market surveillance — are addressed in the FDA frequently asked questions page.

What the System Includes

FDA's regulatory portfolio spans six major product domains, each governed by distinct statutory authority and review standards:

1. Human drugs — Prescription and over-the-counter pharmaceuticals reviewed through the New Drug Application (NDA), Abbreviated New Drug Application (ANDA), or Biologics License Application (BLA) pathways, depending on product type.
2. Biological products — Vaccines, blood products, tissues, allergenics, and gene therapies regulated under the Public Health Service Act in addition to the FD&C Act.
3. Medical devices — Classified into three risk tiers (Class I, II, and III), with market entry requirements ranging from registration alone to full premarket approval. The FDA drug approval process and parallel device pathways are among the most-consulted topics on this site.
4. Food and dietary supplements — Governed primarily through preventive controls, facility registration, and labeling requirements established and expanded by the Food Safety Modernization Act of 2011.
5. Tobacco products — Regulated since the Family Smoking Prevention and Tobacco Control Act of 2009 granted FDA authority over manufacturing, marketing, and distribution of tobacco products.
6. Cosmetics and radiation-emitting products — Subject to lighter premarket requirements but still subject to adulteration and misbranding prohibitions, post-market surveillance, and recall authority.

This site, part of the broader reference network at authoritynetworkamerica.com, covers all six domains across more than 44 topic-specific pages — from FDA centers and offices to emergency use authorization frameworks and digital health software regulation.

Core Moving Parts

Three structural elements determine how FDA actually functions day to day: its organizational architecture, its funding model, and its scientific review centers.

Organizational structure — The agency is headed by a Commissioner appointed by the President and confirmed by the Senate, supported by deputy commissioners and a network of program offices. Below that level, product-specific review authority sits within specialized centers. The FDA organizational structure page maps the full hierarchy, including the Office of Regulatory Affairs (ORA), which houses the field inspection and import compliance workforce.

Funding — FDA operates on a dual funding model combining congressional appropriations with industry-paid user fees authorized under the Prescription Drug User Fee Act (PDUFA) and its medical device, generic drug, and biosimilar counterparts. In fiscal year 2023, user fees accounted for approximately 45% of the agency's total budget (FDA, Justification of Estimates for Appropriations Committees, FY2023). The implications of this funding structure — including the review timeline commitments user fees purchase — are detailed on the FDA budget and funding page.

Review centers — Product categories are assigned to dedicated scientific centers. The Center for Drug Evaluation and Research (CDER) handles most human drugs; the Center for Biologics Evaluation and Research (CBER) oversees vaccines and blood products; the Center for Devices and Radiological Health (CDRH) reviews medical devices; and the Center for Food Safety and Applied Nutrition (CFSAN) oversees packaged food, dietary supplements, and cosmetics. Each center maintains its own guidance documents, review standards, and enforcement posture. A complete breakdown appears on the FDA centers and offices page.

The intersection of these three elements — authority, money, and scientific expertise — defines where FDA acts quickly, where it faces resource constraints, and where regulated industries encounter the most friction in the approval and compliance cycle.